[go: up one dir, main page]

DK0598029T3 - Retrovirale vektorer indeholdende interne ribosome indgangssteder - Google Patents

Retrovirale vektorer indeholdende interne ribosome indgangssteder

Info

Publication number
DK0598029T3
DK0598029T3 DK92917724T DK92917724T DK0598029T3 DK 0598029 T3 DK0598029 T3 DK 0598029T3 DK 92917724 T DK92917724 T DK 92917724T DK 92917724 T DK92917724 T DK 92917724T DK 0598029 T3 DK0598029 T3 DK 0598029T3
Authority
DK
Denmark
Prior art keywords
ribosome entry
internal ribosome
entry sites
vectors containing
retroviral vectors
Prior art date
Application number
DK92917724T
Other languages
English (en)
Inventor
W French Anderson
Richard A Morgan
Larry Couture
Original Assignee
W French Anderson
Richard A Morgan
Larry Couture
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24981978&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0598029(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by W French Anderson, Richard A Morgan, Larry Couture filed Critical W French Anderson
Application granted granted Critical
Publication of DK0598029T3 publication Critical patent/DK0598029T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32211—Cardiovirus, e.g. encephalomyocarditis virus
    • C12N2770/32222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Optical Radar Systems And Details Thereof (AREA)
  • Traffic Control Systems (AREA)
  • Fittings On The Vehicle Exterior For Carrying Loads, And Devices For Holding Or Mounting Articles (AREA)
  • Road Signs Or Road Markings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Molds, Cores, And Manufacturing Methods Thereof (AREA)
DK92917724T 1991-08-07 1992-08-06 Retrovirale vektorer indeholdende interne ribosome indgangssteder DK0598029T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74174091A 1991-08-07 1991-08-07
PCT/US1992/006572 WO1993003143A1 (en) 1991-08-07 1992-08-06 Retroviral vectors containing internal ribosome entry sites

Publications (1)

Publication Number Publication Date
DK0598029T3 true DK0598029T3 (da) 2002-05-27

Family

ID=24981978

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92917724T DK0598029T3 (da) 1991-08-07 1992-08-06 Retrovirale vektorer indeholdende interne ribosome indgangssteder

Country Status (8)

Country Link
EP (1) EP0598029B1 (da)
JP (1) JP3378962B2 (da)
AT (1) ATE213779T1 (da)
CA (1) CA2114416C (da)
DE (1) DE69232438T2 (da)
DK (1) DK0598029T3 (da)
ES (1) ES2173082T3 (da)
WO (1) WO1993003143A1 (da)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4228457A1 (de) * 1992-08-27 1994-04-28 Beiersdorf Ag Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen
DE4228458A1 (de) * 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
US5589582A (en) * 1992-10-27 1996-12-31 Biotransplant, Inc. Polynucleotides en coding porcine cytokines
BE1006437A3 (fr) * 1992-12-10 1994-08-30 Company S A Z Sequence nucleotidique destinee au traitement du cancer et des infections.
AU6230394A (en) * 1993-01-20 1994-11-21 Biotransplant Incorporated Retroviral vectors capable of expressing multimeric proteins from multiple translational initiation sites
CA2159639A1 (en) * 1993-04-02 1994-10-13 Vincent J. Miles Method for selective inactivation of viral replication
US6824976B1 (en) 1993-04-02 2004-11-30 Rigel Pharmaceuticals, Inc. Method for selective inactivation of viral replication
JPH08509606A (ja) * 1993-04-20 1996-10-15 ロビンソン，ウィリアム エス． 細胞内感染因子に感染した個体を処置する方法および物質
GB9320548D0 (en) * 1993-10-06 1993-11-24 Sandoz Ltd Improvements in or relating to organic compounds
GB2284210B (en) * 1993-11-26 1997-11-12 British Tech Group Translational enhancer DNA from a kinesin gene
US6995008B1 (en) 1994-03-07 2006-02-07 Merck & Co., Inc. Coordinate in vivo gene expression
FR2722208B1 (fr) * 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
FR2724320B1 (fr) * 1994-09-13 1996-12-20 Transgene Sa Nouvel implant pour le traitement des maladies acquises
AU780164B2 (en) * 1994-09-13 2005-03-03 Transgene S.A. Novel implant and novel vector for the treatment of acquired diseases
US5518042A (en) * 1994-09-16 1996-05-21 Huyck Licensco, Inc. Papermaker's forming fabric with additional cross machine direction locator and fiber supporting yarns
AT403167B (de) * 1994-11-14 1997-11-25 Immuno Ag Selektion und expression von fremdproteinen mittels eines selektions-amplifikations-systems
DE19514310A1 (de) * 1995-04-18 1996-10-24 Univ Ludwigs Albert Vektoren zur Transfektion von eukaryotischen Zellen, deren Verwendung und damit transfizierte Zielzellen
KR19990022157A (ko) * 1995-06-02 1999-03-25 앰앤드이 바이오테크 아/에스 생물학적으로 활성인 펩티드 및 핵산을 확인하는 방법
GB9517263D0 (en) * 1995-08-23 1995-10-25 Cancer Res Campaign Tech Expression systems
WO1997014809A2 (en) * 1995-10-16 1997-04-24 Dana-Farber Cancer Institute Novel expression vectors and methods of use
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
EP1295952A3 (en) 1996-01-23 2003-07-09 The Board of Trustees of The Leland Stanford Junior University Methods for screening for transdominant effector peptides and RNA molecules
US6365344B1 (en) 1996-01-23 2002-04-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening for transdominant effector peptides and RNA molecules
FR2751345B1 (fr) * 1996-07-16 1998-09-18 Univ Paris Curie Lignees d'encapsidation hautement productrices
FR2755975B1 (fr) * 1996-11-15 1999-05-07 Rhone Poulenc Rorer Sa Virus recombinants bicistroniques utiles pour le traitement de pathologies liees aux dyslipoproteinemies
FR2762615B1 (fr) 1997-04-28 1999-07-16 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes et vecteur le contenant
EP0938904A1 (en) * 1998-02-09 1999-09-01 Leuven Research & Development vzw Mammalian cell transduction for use in gene therapy
EP0980264A2 (en) * 1997-05-16 2000-02-23 Leuven Research & Development vzw Mammalian cell transduction for use in gene therapy
FI110323B (fi) * 1997-06-02 2002-12-31 Timo Korpela Rekombinanttikonstrukti geenin ilmentämisen lisäämiseksi kasveissa
DE69940521D1 (de) 1998-10-01 2009-04-16 Univ Southern California Retrovirales genübertragungssystem und entsprechendes verwendungverfahren
CA2371946A1 (en) * 1999-04-29 2000-11-09 Aarhus University Expression of heterologous genes from an ires translational cassette in retroviral vectors
AU2001271614B2 (en) 2000-07-03 2007-05-31 Catalent Pharma Solutions, Llc Host cells containing multiple integrating vectors
EP1297168A2 (en) 2000-07-03 2003-04-02 Gala Design, Inc. Expression vectors
WO2002014473A2 (en) 2000-08-15 2002-02-21 Board Of Trustees Of The University Of Illinois Animals expressing exogenous igf-i in their milk
GB0024550D0 (da) 2000-10-06 2000-11-22 Oxford Biomedica Ltd
US7419829B2 (en) 2000-10-06 2008-09-02 Oxford Biomedica (Uk) Limited Vector system
EP1217071B1 (en) 2000-12-22 2010-04-28 Institut National De La Recherche Agronomique Position-independent and tissue specific expression of a transgene in milk of transgenic animals
US7384738B2 (en) 2002-03-28 2008-06-10 Bremel Robert D Retrovirus-based genomic screening
US20040038304A1 (en) 2002-03-28 2004-02-26 Gala Design, Inc. Antibody libraries
US20050014932A1 (en) 2003-05-15 2005-01-20 Iogenetics, Llc Targeted biocides
US20070065912A1 (en) 2005-07-21 2007-03-22 Abbott Laboratories Multiple Gene Expression including sORF Constructs and Methods with Polyproteins, Pro-Proteins, and Proteolysis
US8685720B2 (en) 2006-11-03 2014-04-01 The Trustees Of Princeton University Engineered cellular pathways for programmed autoregulation of differentiation
WO2013078433A1 (en) 2011-11-23 2013-05-30 University Of Hawaii Auto-processing domains for polypeptide expression
JP6279466B2 (ja) 2012-04-27 2018-02-14 Ｊｃｒファーマ株式会社 新規な発現ベクター
EP2909324B1 (en) 2012-10-25 2020-02-26 Tocagen Inc. Retroviral vector with mini-promoter cassette

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990001550A1 (en) * 1988-07-29 1990-02-22 Zymogenetics, Inc. High efficiency translation of polycistronic messages in eucaryotic cells

Also Published As

Publication number Publication date
JP3378962B2 (ja) 2003-02-17
CA2114416A1 (en) 1993-02-18
EP0598029A4 (en) 1996-04-17
JPH06509713A (ja) 1994-11-02
EP0598029B1 (en) 2002-02-27
DE69232438T2 (de) 2002-10-10
ATE213779T1 (de) 2002-03-15
EP0598029A1 (en) 1994-05-25
DE69232438D1 (de) 2002-04-04
CA2114416C (en) 1998-07-07
WO1993003143A1 (en) 1993-02-18
ES2173082T3 (es) 2002-10-16

Similar Documents

Publication Publication Date Title
DK0598029T3 (da) Retrovirale vektorer indeholdende interne ribosome indgangssteder
IE44226L (en) Hentriakontapeptides
GR3014924T3 (en) Mammalian expression of the bmp-2 family.
NL1002835A1 (nl) Synergistisch stabilisatormengsel.
FI855141A7 (fi) Rekombinantti-DNA-vektoreita, jotka kykenevät ilmaisemaan apoaequoriinia.
FI923280A0 (fi) Aminosubstituerade piperazinderivat.
DE69114988D1 (de) Harzmischung für Pulverlacke.
ATE133183T1 (de) Peptide, die von der faktor viii-bindungsdomäne des von willebrand-faktors abgeleitet sind
DE69327443D1 (de) Multiplexer, an dessen Eingang mehrere identische Signale verschiedener Phasenlage anliegen
EP0123950A3 (en) Intermediates for thymosin alpha 1 and desacetylthymosin alpha 1
FI961044A0 (fi) Kininogeeni-inhibiittorit
MX18879A (es) Analogos de la prostaglandina de amida heterociclica substituida con 7-oxabicicloheptilo.
DK0852587T3 (da) Syntetiske peptider der inhiberer IL-6-aktivitet
FI970892L (fi) Ilmentymiseltään kohdennetut retrovirusvektorit, jotka eivät ole itsestään inaktivoivia
BR9407693A (pt) Sequência nucleotídica vetor composiçao farmacêutica utilizaçao do vetor e de um composto
ATE177432T1 (de) Antikoagulierende peptide
EP0127727A3 (en) Substituted n-(omega-(1h-imidazol-1-yl)alkyl)) amides
DE69122103D1 (de) Antigerinnungspeptide
EP0179412A3 (en) Antigenic peptide compounds
IT8722485A0 (it) Preparazione di composti epossidici a configurazione cis e trans apartire da miscele degli stereoisomeri olefinici corrispondenti.
MX9202871A (es) 5-(amino substituidas)-8-(fenil substituidas)-3h,6h-1,4,5a,8a-tetraazaacenaf-tilen-3-onas.
EA199900253A1 (ru) Ptx-чувствительные g-протеины, их получение и применение
FI941394A0 (fi) Peptidejä,jotka kykenevät säätelemään akrosomireaktiota
SE9402253D0 (sv) Process
MA21633A1 (fr) Sunthese peptidiques en phase solide.